Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors

Nature Medicine

Volumn 17, Issue 7, 2011, Pages 854-859

  Kottke, Timothy ^a   Errington, Fiona ^b   Pulido, Jose ^a   Galivo, Feorillo ^a   Thompson, Jill ^a   Wongthida, Phonphimon ^a   Diaz, Rosa Maria ^a   Chong, Heung ^c   Ilett, Elizabeth ^b   Chester, John ^b   Pandha, Hardev ^d   Harrington, Kevin ^e   Selby, Peter ^b   Melcher, Alan ^b   Vile, Richard ^a,b,f  

^a MAYO CLINIC   (United States)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF SURREY   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN; VIRUS VECTOR;

ALTERED SELF ANTIGEN AND EPITOPE LIBRARY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; DNA IMMUNIZATION; DNA LIBRARY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DNA, COMPLEMENTARY; GENE LIBRARY; GENETIC VECTORS; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; VESICULOVIRUS;

EID: 79960125220     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2390     Document Type: Article

References (44)

1. Drake, C.G., Jaffee, E.M. & Pardoll, D.M. Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51-81 (2006). (Pubitemid 43765799)
2. Koos, D. et al. Tumor vaccines in 2010: need for integration. Cell. Immunol. 263, 138-147 (2010).
3. Le, D.T., Pardoll, D.M. & Jaffee, E.M. Cellular vaccine approaches. Cancer J. 16, 304-310 (2010).
4. Parato, K.A., Lichty, B.D. & Bell, J.C. Diplomatic immunity: turning a foe into an ally. Curr. Opin. Mol. Ther. 11, 13-21 (2009).
5. Prestwich, R.J. et al. Oncolytic viruses: a novel form of immunotherapy. Expert Rev. Anticancer Ther. 8, 1581-1588 (2008).
6. Smyth, M.J., Dunn, G.P. & Schreiber, R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90, 1-50 (2006). (Pubitemid 43765795)
7. Daniels, G.A. et al. A simple method to cure established tumors by inflammatory killing of normal cells. Nat. Biotechnol. 22, 1125-1132 (2004). (Pubitemid 39166850)
8. Kottke, T. et al. Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res. 69, 7767-7774 (2009).
9. Kottke, T. et al. Induction of hsp70-mediated, TH17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res. 67, 11970-11979 (2007).
10. Sanchez-Perez, L. et al. Killing of normal melanocytes, combined with hsp70 and CD40L expression, cures large established melanomas. J. Immunol. 177, 4168-4177 (2006). (Pubitemid 44359952)
11. Sanchez-Perez, L. et al. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 65, 2009-2017 (2005). (Pubitemid 40478631)
12. Ferrone, S. Immunotherapy dispenses with tumor antigens. Nat. Biotechnol. 22, 1096-1098 (2004). (Pubitemid 39166844)
13. Turk, M.J., Wolchok, J.D., Guevara-Patino, J.A., Goldberg, S.M. & Houghton, A.N. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 188, 122-135 (2002). (Pubitemid 35398870)
14. Braxton, C.L., Puckett, S.H., Mizel, S.B. & Lyles, D.S. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J. Virol. 84, 3552-3561 (2010).
15. Cobleigh, M.A., Bouonocore, L., Uprichard, S.L., Rose, J.K. & Robek, M.D. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J. Virol. 84, 7513-7522 (2010).
16. Geisbert, T.W. et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J. Virol. 83, 7296-7304 (2009).
17. Schwartz, J.A. et al. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J. Virol. 84, 4611-4618 (2010).
18. Bridle, B.W. et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol. Ther. 17, 1814-1821 (2009).
19. Bridle, B.W. et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther. 18, 1430-1439 (2010).
20. Diaz, R.M. et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 67, 2840-2848 (2007). (Pubitemid 46548974)
21. Ilett, E.J. et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther. 16, 689-699 (2009).
22. Prestwich, R.J. et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin. Cancer Res. 15, 4374-4381 (2009).
23. Qiao, J. et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat. Med. 14, 37-44 (2008).
24. Flatz, L. et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat. Med. 16, 339-345 (2010).
25. Guevara-Patiño, J.A. et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J. Clin. Invest. 116, 1382-1390 (2006).
26. Guevara-Patiño, J.A., Turk, M.J., Wolchok, J.D. & Houghton, A.N. Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv. Cancer Res. 90, 157-177 (2003). (Pubitemid 37549224)
27. Overwijk, W.W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569-580 (2003). (Pubitemid 37040391)
28. Hogquist, K.A. et al. T cell receptor antagonistic peptides induce positive selection. Cell 76, 17-27 (1994). (Pubitemid 24035278)
29. Berx, G. & van Roy, F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb. Perspect. Biol. 1, a003129 (2009).
30. Kalluri, R. & Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428 (2009).
31. Moody, S.E. et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8, 197-209 (2005). (Pubitemid 41317591)
32. Santisteban, M. et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 69, 2887-2895 (2009).
33. Overwijk, W.W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569-580 (2003). (Pubitemid 37040391)
34. Motrich, R.D., Maccioni, M., Riera, C.M. & Rivero, V.E. Autoimmune prostatitis: State of the art. Scand. J. Immunol. 66, 217-227 (2007). (Pubitemid 47063198)
35. Thorne, S.H. & Contag, C.H. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. Gene Ther. 15, 753-758 (2008). (Pubitemid 351627358)
36. Willmon, C. et al. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol. Ther. 17, 1667-1676 (2009).
37. Dumas, F. et al. Molecular expression of PSMA mRNA and protein in primary renal tumors. Int. J. Cancer 80, 799-803 (1999). (Pubitemid 29108851)
38. Kiessling, A. et al. Advances in specific immunotherapy for prostate cancer. Eur. Urol. 53, 694-708 (2008).
39. Reiter, R.E. et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 95, 1735-1740 (1998). (Pubitemid 28103463)
40. Tsavaler, L., Shapero, M.H., Morkowski, S. & Laus, R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 61, 3760-3769 (2001). (Pubitemid 32694990)
41. Tanaka, S. et al. Target killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter. Cancer Gene Ther. 7, 1241-1250 (2000).
42. Yang, D., Holt, G.E., Velders, M.P., Kwon, E.D. & Kast, W.M. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res. 61, 5857-5860 (2001). (Pubitemid 32769105)
43. Sanchez-Perez, L. et al. Synergy of adoptive T-cell therapy with intratumoral suicide gene therapy is mediated by host NK cells. Gene Ther. 14, 998-1009 (2007). (Pubitemid 46965269)
44. Fernandez, M., Porosnicu, M., Markovic, D. & Barber, G.N. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76, 895-904 (2002). (Pubitemid 34033386)